• Wondering whether Insmed's current share price lines up with its underlying value, or if expectations have simply run ahead of the story.
• The stock last closed at US$150.52, with returns of 1.3% over 7 days, a 6.8% decline over 30 days, a 15.0% decline year to date, and 85.0% over the past year, which naturally raises questions about how much optimism is already in the price.
• Recent news coverage has focused heavily on Insmed's progress and prospects in the pharmaceuticals and biotech space. This often shapes how investors think about future cash flows and risk, and these headlines provide useful context for understanding why the share price and sentiment have moved the way they have.
• Insmed currently has a valuation score of 3 out of 6. We will look at what different valuation methods suggest about that score, then finish by looking at a more complete way to think about valuation beyond any single model.

Approach 1: Insmed Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and then discounting those back to a present value using a required rate of return.

For Insmed, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is a loss of about US$906.7 million. Analysts provide explicit forecasts out to 2030, where free cash flow is projected at about US$2.4 billion, and Simply Wall St extrapolates further years from those inputs.

When these projected cash flows are discounted back, the DCF model arrives at an estimated intrinsic value of about US$387.62 per share. Compared with the recent share price of US$150.52, this indicates the shares are trading at a 61.2% discount to that modelled value, so on this basis the stock appears undervalued according to the model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Insmed is undervalued by 61.2%. Track this in your watchlist or portfolio, or discover 56 more high quality undervalued stocks.

Approach 2: Insmed Price vs Book

For companies in healthcare and biotech that may not yet be consistently profitable, price-based multiples like P/B are often more useful than earnings-based measures such as P/E. Book value gives you a snapshot of what the market is paying for the company’s net assets today.

In general, investors tend to accept a higher “normal” or “fair” multiple when they expect stronger growth and see fewer risks, and a lower multiple when growth looks more modest or the risk profile feels higher. That same logic applies to P/B, where a higher ratio usually reflects higher expectations for what the company can do with its asset base over time.

Insmed is currently trading on a P/B of 33.95x. This compares with an average P/B of 2.61x for the Biotechs industry and a peer group average of 7.99x. Simply Wall St’s Fair Ratio is a proprietary estimate of what Insmed’s P/B “should” be based on factors such as earnings growth, profit margins, industry, market cap and key risks. That makes it a more tailored yardstick than a simple comparison with peers or the broad industry, which may not share the same risk and growth profile.

Because the Fair Ratio is not available here, we cannot say whether 33.95x points to Insmed being overvalued, undervalued, or about right on this measure.

Result: ABOUT RIGHT

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 23 top founder-led companies.

Upgrade Your Decision Making: Choose your Insmed Narrative

Earlier we mentioned that there is an even better way to think about valuation, and on Simply Wall St that means using Narratives, where you write the story you believe about Insmed, link that story to your own forecast for revenue, earnings and margins, and end up with a fair value that you can compare directly with the current price.

A Narrative is essentially your investment thesis written in plain language, then translated into numbers. Instead of only relying on the analyst consensus fair value of about US$214.37 or price targets between US$89.00 and US$110.00, you can decide whether you see Insmed closer to the bullish case that assumes strong earnings and a future P/E around 84.46x, or nearer the cautious view that assumes weaker earnings or even continued losses.

On the Simply Wall St Community page, Narratives are easy to create and update. They refresh automatically when new earnings, news or guidance arrives, and they help you decide if Insmed looks attractive, fairly priced or expensive for you personally by continually lining up your fair value against the live share price.

Do you think there's more to the story for Insmed? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.